Background/Aims: Nuclear factor erythroid 2-related factor 2 (Nrf2) is an oncogene in various types of cancers, including oral squamous cell carcinoma (OSCC). Oxysophocarpine (OSC) is a natural alkaloid that has multiple phar macological activities. However, the biological functions and molecular mechanism underlying the effects of OSC on the growth and metastasis of OSCC are unclear. Methods: Nrf2 levels were determined in OSCC tissues and non-cancerous specimens by quantitative real-time PCR, western blotting, and immunohistochemistry (IHC) assays. The effects of OSC on OSCC cell growth and metastasis were explored (1) using 5-ethynyl-20-deoxyuridine staining and Cell Counting Kit-8, colony formation, flow cytometry, wound-healing, Transwell, and tube formation assays in vitro; and (2) by establishing a xenograft nude mouse model in vivo. The molecular mechanisms underlying the effects of OSC on the growth and metastasis of OSCC were investigated in vitro by western blotting, caspase-3 activity, and enzyme-linked immunosorbent assays, and in vivo by western blotting and IHC assays. Results: The expression levels of Nrf2 in OSCC tissues and in cell lines were much higher than in non-cancerous tissues and normal oral keratinocytes. The upregulation of Nrf2 was positively correlated with a high incidence of lymph node metastasis and advanced histological grade and TNM stage, but inversely associated with differentiation and survival of 
Introduction
Oral squamous cell carcinoma (OSCC), the major type (> 90%) of oral cancer worldwide, is one of the most aggressive cancers [1, 2] . The well-established etiological factors of OSCC include tobacco usage, alcohol consumption, betel quid chewing, and human papillomavirus infection [3, 4] . Despite considerable improvements in the combination of surgery, radiotherapy, and chemotherapy, the 5-year survival rate of OSCC patients remains less than 50% [5] . Excessive proliferation, local invasion, distant metastasis, and recurrence are considered the most important adverse prognostic factors for OSCC [6, 7] . Thus, the molecular mechanisms underlying OSCC progression and effective therapeutic agents against OSCC need to be explored.
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a redox-sensitive transcription factor that controls the expression of various antioxidant and cytoprotective genes regulating the cellular response to oxidative and electrophilic stresses [8] . Under basal conditions, Nrf2 is sequestered by the Kelch-like ECH-associated protein 1 (Keap1), which is a Cul3-based E3 ubiquitin ligase adapter that leads to Nrf2 ubiquitination and proteasome-dependent degradation [9] . Under conditions of oxidative stress, Keap1 is modified and allows Nrf2 to be released and translocate into the nucleus where it recognizes an enhancer sequence known as the antioxidant-response element, resulting in the transcription of antioxidants, phase II detoxification enzymes, and drug transporters [10] [11] [12] . Nrf2 is a primary cellular defense protein against the cytotoxic effects of oxidative stress; thus, Nrf2 has been traditionally considered as a tumor suppressor [13] . However, mounting evidence revealed the potential oncogenic roles of Nrf2 and its transcriptional target genes, such as heme oxygenase 1 (HO-1) [14, 15] , one of the main effectors of Nrf2-dependent cell responses [15] . Nrf2 is highly expressed in many types of tumors, including OSCC [16] [17] [18] [19] [20] [21] [22] . Moreover, the enhancement of Nrf2 expression can be considered a poor prognostic factor [16, 17] . Nrf2/HO-1 signaling activation promotes metastasis, angiogenesis, and chemotherapy and radiotherapy resistance of cancer cells [14, 15] . Fan et al [23] . showed that Nrf2 overexpression increases proliferation, migration, and invasion of OSCC cells by regulating Notch signaling. However, the functional roles of the Nrf2/HO-1 axis in the regulation of aggressive phenotypes of OSCC are largely unknown.
Oxysophocarpine (OSC) is a quinolizidine alkaloid isolated from Sophora flavescens Ait. (Kushen), S. alopecuroides L. (Kudouzi or Kugancao), and other leguminous plants of the genus Robinia [24] . OSC is a widely used traditional Chinese medicine and has antinociceptive [25] , neuroprotective [26, 27] , analgesic [28] , and anti-viral [29, 30] activities through anti-apoptotic, anti-inflammatory, and immunosuppressive effects. OSC has been demonstrated to exert anti-cancer activity, but few studies have focused on the effects of OSC on cancer [31] . Previously, OSC was reported to suppress the proliferation and promote the apoptosis of PC-3 prostate cancer cells [32] . However, whether OSC produces anti-OSCC effects remains unclear.
In this study, Nrf2 was highly expressed in OSCC tissues and cell lines. Increased expression of Nrf2 was positively associated with lymphatic and distant metastases, high histological grades, and advanced stages, but negatively associated with tumor differentiation and the prognosis of OSCC patients. OSC 
Materials and Methods

Patients and samples
Cancer and corresponding non-cancerous tissue samples were obtained from 96 OSCC patients who underwent surgical resection at the School and Hospital of Stomatology, Wenzhou Medical University between July 2008 and April 2012; the followup period for survival analyses ended in April 2017. None of the patients received preoperative chemotherapy or radiotherapy, and written informed consent was obtained from all patients. This study was approved by the ethics committee of Wenzhou Medical University, and all the experimental procedures were performed in accordance with the National Institutes of Health guidelines. The tumor tissues were analyzed by pathological examination and classified using the World Health Organization classification system; clinical stage was determined by the tumor-node-metastasis (TNM) classification of the American Joint Committee on Cancer. Clinicopathological characteristics of the patients are summarized in Table 1 . A total of 96 pairs of paraffin-embedded cancer and non-cancerous tissue specimens were collected for immunohistochemistry (IHC) staining and 30 pairs of freshly isolated OSCC and the corresponding noncancerous tissues were stored in liquid nitrogen for quantitative real-time PCR (qPCR) assay and western blot analysis.
Cell culture, transfection, and treatment
Five human OSCC cell lines (Tca8113, Cal27, SCC-9, SCC-15, and SCC-25) were purchased from American Type Culture Collection (ATCC; Manassas, VA) and cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Carlsbad, CA). Human normal oral keratinocytes (hNOKs; ScienCell Research Laboratories, Carlsbad, CA) were maintained in oral keratinocyte medium (ScienCell Research Laboratories). Human umbilical vein endothelial cells (HUVECs; ATCC) were cultivated in M200 medium (Cascade Biologics, Portland, OR). All cell lines were supplemented with 10% fetal bovine serum (FBS; Gibco BRL), 100 U/ ml penicillin, and 100 μg/ml streptomycin (Sigma-Aldrich, St. Louis, MO) in a humidified atmosphere with 5% CO 2 at 37°C. The small interfering RNA-targeting Nrf2 (siNrf2), HO-1 (siHO-1), and the negative control siRNA (siNC) were synthesized by GenePharma (Shanghai, China) and transfected into SCC-9 and SCC-15 cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in accordance with the manufacturer's 
qPCR assay
Total RNA was isolated from fresh tissues and cultured cells using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. Reverse transcription was performed with 1 μg total RNA using the PrimeScript RT Reagent Kit (Takara, Dalian, China). The qPCR assay was performed using an ABI 7500 real-time PCR system (Applied Biosystems, Foster City, CA) with a SYBR Green Real-time PCR Kit (Takara). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control. The relative expression of Nrf2 was calculated using the 2 −ΔΔCt method. The following primers were used: for Nrf2, forward 5′-AGCAGGCTGAGACTACCACT-3′ and reverse 5′-TCCAGTGAGGGGATCGATGA-3′; for GAPDH, forward 5′-CATCTCTGCCCCCTCTGCTGA-3′ and reverse 5′-GGATGACCTTGCCCACAGCCT-3′.
Western blot analysis
Protein was extracted from tissue specimens and cultured cells using RIPA lysis buffer (Beyotime, Shanghai, China) and the concentration was determined using a BCA Protein Assay Kit (Beyotime). Equal amounts of protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred onto polyvinylidene-fluoride membranes (Millipore, Bedford, MA). After blocking with 5% non-fat milk in Tris-buffered saline and Tween 20 for 1 h at room temperature, the membranes were incubated with primary antibodies against Nrf2, HO-1, proliferating cell nuclear antigen (PCNA), cyclin D1, Bcl-2, Bax (Abcam, Cambridge, UK), E-cadherin, vimentin, matrix metalloproteinase-9 (MMP-9), hypoxia-inducible factor 1α (HIF-1α), vascular endothelial growth factor (VEGF), and GAPDH (Cell Signaling Technology Beverly, MA) at 4°C overnight, followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies (Abcam) at 37°C for 1 h. GAPDH was used as the loading control. Protein bands were analyzed using an enhanced chemiluminescence kit (Pierce Biotechnology, Rockford, IL) with an imaging system (Bio-Rad Laboratories, Hercules, CA).
IHC staining
Paraffin-embedded tissues were sectioned (4 μm thick), deparaffinized with xylene, and dehydrated in a series of graded ethanol solutions. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide at room temperature for 15 min, and the sections were then boiled in citrate buffer for 10 min at 121°C in a microwave oven to retrieve antigenicity. The sections were incubated with primary antibodies against Nrf2, HO-1, PCNA, cyclin D1, Bcl-2, Bax, E-cadherin, vimentin, MMP-9, HIF-1α, and VEGF at 4°C overnight, followed by incubation with a biotin-labeled secondary antibody (Vector Laboratories, Burlingame, CA) at 37°C for 1 h. Sections were stained with diaminobenzidine, counterstained with hematoxylin, and observed under a light microscope (Olympus, Tokyo, Japan). Immunostaining was classified into two groups according to intensity and extent. Intensity scores were expressed as follows: 0, negative staining; 1, weak staining; 2, moderate staining; and 3, strong staining. Extent scores (percentage of tumor cells stained positive) were represented as follows: 0, < 20% of cells; 1, 20% to 50% of cells; and 3, > 50% of the cells. The final staining score (intensity × extent) varied from 0 to 9 for each spot. According to the final scores, the tissues were divided into two groups: Nrf2 low expression group (score ≤ 3) and Nrf2 high expression group (score > 3).
Cell viability assay
Cell viability was measured using the Cell Counting Kit-8 (CCK-8) assay (Dojindo Laboratories, Tokyo, Japan) according to the manufacturer's protocol. After different treatments, SCC-9 and SCC-15 cells were seeded in 96-well plates at a density of 1 × 10 
5-Ethynyl-20-deoxyuridine incorporation assay
Cell proliferation was assessed using a 5-ethynyl-20-deoxyuridine (EdU) incorporation assay following the manufacturer's instructions. Briefly, SCC-9 and SCC-15 cells were seeded in six-well plates and subjected to different treatments for 24 h. EdU (50 μM; RiboBio, Guangzhou, China) was added into each well, and cells were cultured for 2 h, followed by fixing with 4% paraformaldehyde for 20 min at room temperature. The plates were observed and photographed under an inverted fluorescent microscope (Olympus).
Colony formation assay
For colony formation assay, SCC-9 and SCC-15 cells subjected to various treatments were plated in six-well plates at a density of 1 × 10 3 /well and incubated in DMEM containing 10% FBS at 37°C for 14 days in a humidified chamber with 5% CO 2 . Fresh culture medium was replaced every 2 days. The cells were then fixed with methanol and stained with 0.1% crystal violet (Sigma-Aldrich). Colony formation was determined by counting the number of visible colonies.
Cell cycle analysis
The cell cycle was analyzed by flow cytometry. In brief, SCC-9 and SCC-15 cells subjected to various treatments were harvested and fixed with 70% cold ethanol for 2 h. RNasw was added (1 mg/ml; Takara) and cells were incubated at 37°C for 30 min. Intracellular DNA was labeled with 50 μg/ml propidium iodide (PI; Sigma-Aldrich) at 4°C for 30 min. The samples were assayed using a FACScan flow cytometer (BD Biosciences, San Jose, CA). The results were analyzed using CELL Quest 3.0 software (BD Biosciences).
Apoptosis assay by flow cytometry
Cell apoptosis was analyzed by flow cytometry using an Annexin V/Fluorescein isothiocyanate (FITC) and PI Apoptosis Detection Kit (BD Biosciences) according to the manufacturer's protocol. In brief, SCC-9 and SCC-15 cells subjected to different treatments were harvested, centrifuged, and resuspended in 1× binding buffer at a final concentration of 1 × 10 6 cells/ml. Annexin V/FITC (10 μl) was added in the mixture, incubated at 37°C for 15 min, and counterstained with PI (5 μl) in the dark for 30 min. Annexin V/FITC and PI fluorescence were determined using the FACSCalibur flow cytometer. Results were analyzed using CELL Quest 3.0 software.
Caspase-3 activity assay
Caspase-3 activity was measured using the Caspase-3/CPP32 Colorimetric Assay Kit (BioVision, Palo Alto, CA) in accordance with the manufacturer's instruction. After various treatments, SCC-9 and SCC-15 cells (1 × 10 6 ) were lyzed, and the supernatant was collected. Protein (150 μg) was added to 2× reaction buffer containing 5 μl N-Acetyl-Asp-Glu-Val-Asp-pNA substrate (200 μM final concentration) and incubated at 37°C for 2 h. N-Acetyl-Asp-Glu-Val-Asp-pNA cleavage was determined by measuring enzyme-catalyzed release of pNA at 405 nm using a microplate reader (Bio-Rad Laboratories).
Wound-healing assay SCC-9 and SCC-15 cells subjected to various treatments were seeded in six-well plates and incubated for 24 h in a humidified chamber with 5% CO 2 at 37°C. Wounds were made using a 200-μl pipette tip on a confluent cell monolayer. The cells were continuously incubated for 48 h, and wound closure was observed. Photographs were captured at 0 and 48 h with a phase-contrast microscope (Olympus).
Transwell assays
Cell migration and invasion were assessed by Transwell assays. For the migration assay, SCC-9 and SCC-15 cells subjected to various treatments were seeded into the upper chamber of the Transwell apparatus (8-μm pore size; Corning Costar, Dallas, TX) with serum-free DMEM. The lower chamber was filled with DMEM containing 15% FBS as a chemoattractant. The procedure for the invasion assay was similar to that of the migration assay, except that the Transwell membranes were pre-coated with 200 μg/ml Matrigel (BD Biosciences). After incubation for 24 h, cells that had migrated or invaded through the membrane were fixed with methanol, stained with crystal violet, and counted using a microscope (Olympus). ) were seeded into 24-well plates pre-coated with Matrigel and cultured in M200 medium containing 50 μl conditioned medium (CM) freshly collected from SCC-9 and SCC-15 cells subjected to various treatments. After incubation for 36 h, tube formation was monitored and photographed under a phase contrast microscope (Olympus). The tube number, tube branch points, and relative tubule length were determined.
Enzyme-linked immunosorbent assay VEGF release from SCC-9 and SCC-15 cells subjected to various treatments was measured by enzymelinked immunosorbent assay (ELISA) using a commercial kit (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. In brief, cell supernatants or standards (200 μl) were added to the microplate pre-coated with monoclonal antibody against VEGF and incubated for 2 h at room temperature, followed by incubation with HRP-conjugated secondary antibody for 2 h at room temperature. Substrate solution was then added and cells were incubated for 30 min until stop solution was added to stop the reaction. The absorbance was measured at 450 nm on a microplate reader (Bio-Rad Laboratories). Results were expressed as pg/ml.
In vivo xenograft tumor model
Six-week-old male BALB/c nude mice (weighing 22-24 g) were purchased from the Institute of Zoology, Chinese Academy of Sciences, Beijing, China and maintained on a standard diet and water under pathogenfree conditions with a regular 12-h day/night cycle. All the experimental procedures were approved by the Institutional Guidelines of Animal Care and Use Committee of Wenzhou Medical University.
For the xenograft tumor formation assay, SCC-9 cells (3 × 10 6 ) mixed with Matrigel were subcutaneously injected into the flanks of mice. When tumor size reached approximately 60 mm 3 , the mice were randomly assigned to control and OSC groups (n = 6 per group). OSC (80 mg/kg) or vehicle control was administered by intraperitoneal injection every 2 days for 3 weeks. Tumor size was monitored once a week, and tumor volume was determined using the formula: tumor volume = (length × width 2 )/2. Six weeks after SCC-9 cell implantation, the animals were killed, and the tumors were immediately collected and weighed. The tumor tissues were fixed with 4% paraformaldehyde and embedded in paraffin for IHC staining or stored at -80°C for western blot analysis.
Statistical analysis
All statistical analyses were performed using the GraphPad Prism 5.0 statistical software package (GraphPad Software, Inc. La Jolla, CA). All data are expressed as the mean ± standard deviation (SD). Differences were analyzed using Student's t test between two groups or one-way analysis of variance for multiple groups. Survival curves were plotted using the Kaplan-Meier method and analyzed using the log rank test. Chi-squared test was used to analyze the relationship between Nrf2 levels and clinicopathological characteristics of patients. P < 0.05 was considered statistically significant.
Results
Upregulation of Nrf2 is positively associated with tumor progression and poor prognosis of OSCC patients
To explore the relationship between Nrf2 expression and OSCC, we measured the mRNA levels of Nrf2 in 30 pairs of OSCC and the corresponding non-cancerous tissue samples by qPCR. As shown in Fig. 1A , the mRNA level of Nrf2 was significantly increased in OSCC tissues compared with non-cancerous samples. Moreover, patients with lymphatic metastasis or tumors at advanced histological grades (III/IV) had higher levels of Nrf2 mRNA compared with cases with non-metastatic or low-stage (I/II) tumors ( Fig. 1B-C ; Table 1 ). Upregulation of Nrf2 was also closely correlated with differentiation and TNM stage but not significantly associated with sex, age, smoking, and alcohol consumption ( Table 1) . The results of western blotting showed that the protein level of Nrf2 was much higher in OSCC tissues than in non-cancerous samples (Fig. 1D) . IHC results also indicated high expression of Nrf2 (Fig. 1E-F) . Furthermore, patients with high Nrf2 expression had poorer survival than those with low Nrf2 expression levels (Fig. 1G) . These results suggest that Nrf2 elevation plays a key role in the development and progression of OSCC and may be a useful prognostic marker for OSCC.
OSC inhibits the Nrf2/HO-1 signaling pathway in OSCC cells
The baseline mRNA and protein expression levels of Nrf2 in the hNOKs and five OSCC cell lines (Tca8113, Cal27, SCC-9, SCC-15, and SCC-25) were measured by qPCR and western blotting assays. Nrf2 was highly expressed both at the mRNA and protein levels in the five OSCC cell lines compared with hNOKs ( Fig. 2A-B) . SCC-9 and SCC-15 cells were selected for subsequent studies because they had the highest Nrf2 levels among the five OSCC cell lines. To evaluate the effect of OSC on Nrf2 and HO-1 expression, we treated SCC-9 and SCC-15 cells with the vehicle control or 3, 5, and 7 μM OSC for 24 h. Nrf2 and HO-1 protein expression levels were decreased in a dose-dependent manner in the SCC-9 and SCC-15 cells, and 5 and 7 μM OSC treatment had similar effects on Nrf2 and HO-1 expression. Thus, 5 μM OSC was selected for subsequent experiments (Fig. 2C) . To verify HO-1 as a target of Nrf2 in OSCC cells, we transfected SCC-9 and SCC-15 cells with siNC or siNrf2 mimics. As shown in Fig.  2D , siNrf2 transfection led to significant reduction in Nrf2 and HO-1 expression compared with siNC-transfected or control cells. These data demonstrate that OSC suppresses Nrf2 and HO-1 expression in OSCC cells. 
OSC induces p r o l i f e r a t i o n inhibition and apoptosis of OSCC cells
To determine the functional role of OSC in cell proliferation, we performed the CCK-8 assay, EdU staining, and colony formation assays. OSC treatment significantly inhibited the viability of SCC-9 and SCC-15 cells compared with control cells (Fig. 3A) . EdU staining demonstrated a reduction in proliferative SCC-9 and SCC-15 cells in the OSC-treated group (Fig. 3B-C) . The colony formation assays showed substantial reduction in the colonies of OSC-treated SCC-9 and SCC-15 cells (Fig. 3D-E) . OSC administration reduced cell cycle transition from G1 to S phase in SCC-9 and SCC-15 cells compared with the corresponding control cells (Fig. 3F-G) . Next, we explored the effect of OSC on apoptosis of OSCC cells. As shown in Fig. 3H-I , flow cytometry assay indicated that OSC treatment resulted in more apoptotic cells compared with the control SCC-9 and SCC-15 cells. OSC treatment significantly increased caspase-3 activity in SCC-9 and SCC-15 cells (Fig. 3J) . These results indicate that OSC inhibits OSCC cell proliferation and induces apoptosis.
OSC suppresses migration and invasion of OSCC cells
To investigate the effects of OSC on OSCC cell mobility, we performed wound-healing and Transwell assays. As shown in Fig. 4A -B, the wound-healing assay showed that OSC treatment markedly reduced SCC-9 and SCC-15 cell migration compared with the control cells. The reduction in migratory cells caused by OSC was also evidenced by the Transwell assay (Fig. 4C-D) . Moreover, the invasion of SCC-9 and SCC-15 cells was suppressed by OSC treatment (Fig. 4E-F) . These findings suggest that OSC decreases migration and invasion of OSCC cells.
OSC reduces the pro-angiogenic effects of OSCC cells
To examine whether OSC has anti-angiogenic effects on OSCC cells, we treated SCC-9 and SCC-15 cells with OSC or vehicle control for 24 h, and the CM was collected to incubate HUVECs for tube formation assays. As expected, fewer tube formations were observed for HUVECs treated with the CM from OSC-treated SCC-9 and SCC-15 cells compared with control cells (Fig. 5A) . The tube number (Fig. 5B) , tube branch points (Fig. 5C) , and tube length (Fig.  5D ) were considerably reduced in the HUVECs cultured with OSC-treated CM. The secretion of pro-angiogenic growth factor VEGF was also reduced by OSC treatment in SCC-9 and SCC-15 cells (Fig. 5E ). These data suggest that OSC reduces pro-angiogenesis of OSCC cells. 
OSC exerts anti-OSCC effects by inactivating HO-1 signaling
Next, we investigated whether OSC inhibited the proliferation of and facilitated apoptosis in OSCC cells via inactivation of HO-1 signaling. The colony formation assay showed substantial reduction in the colonies of SCC-9 and SCC-15 cells treated with OSC, siHO-1. or the HO-1 inhibitor ZnPP (Fig. 6A) . OSC, siHO-1, or ZnPP treatment significantly increased caspase-3 activity in SCC-9 and SCC-15 cells (Fig. 6B ). Molecular analyses demonstrated that OSC reduced the expression levels of pro-survival proteins including HO-1, PCNA, cyclin D1, and Bcl-2, and enhanced the levels of the pro-apoptotic protein Bax in SCC-9 and SCC-15 cells (Fig. 6C) . Then, we examined the effects of siHO-1 and ZnPP on the expression levels of these proteins. We found that siHO-1 transfection or ZnPP treatment downregulated the levels of PCNA, cyclin D1, and Bcl-2, and upregulated the expression of Bax in SCC-9 and SCC-15 cells, similar to the effects of OSC (Fig. 6C) . Furthermore, we addressed whether OSC hindered the HO-1 signaling-dependent migration and invasion of OSCC cells. As shown in Fig. 6D -E, Transwell assays demonstrated that OSC, siHO-1, or ZnPP treatment markedly decreased SCC-9 and SCC-15 cell migration and invasion compared with control cells. OSC administration resulted in upregulation of E-cadherin and downregulation of HO-1, vimentin, and MMP-9 in SCC-9 and SCC-15 cells (Fig. 6F) . In addition, ZnPP treatment or transfection with siHO-1 led to higher expression of E-cadherin and lower levels of vimentin and MMP-9 in SCC-9 and SCC-15 cells compared with the siNC-transfected or control cells, consistent with the effects of OSC (Fig. 6F) . Then, we investigated whether OSC-suppressed vasculogenic mimicry was dependent on HO-1 signaling. Tube formation assays showed fewer tube formations for HUVECs treated with the CM from SCC-9 and SCC-15 cells treated with OSC, si-HO-1, or ZNPP compared with HUVECs treated with CM from control cells (Fig. 6G) . VEGF release was also reduced by OSC, si-HO-1, or ZnPP treatment in SCC-9 and SCC-15 cells (Fig. 6H) . Accordingly, OSC reduced the expression of pro-angiogenic proteins, including HO-1, HIF-1α, and VEGF (Fig. 6I) . ZnPP treatment or siHO-1 transfection also markedly decreased the expression of 
HIF-1α and VEGF, consistent with the effects of OSC (Fig. 6I) . These results suggest that OSC confers oncostatic effects on OSCC cells by inactivating HO-1 signaling.
OSC hinders tumorigenesis of OSCC in vivo
To investigate whether OSC slows tumorigenesis of OSCC in vivo, we established a xenograft mouse model by implanting SCC-9 cells and then intraperitoneally injecting the nude mice with OSC or the vehicle control every 2 days for 3 weeks. As shown in Fig. 7A , OSC treatment markedly inhibited tumor growth compared with the control group. The tumor size of OSC-administered mice was much smaller than in control mice (Fig. 7B) . OSC treatment also markedly reduced tumor weight compared with the control group (Fig. 7C) . Molecular analyses of the tumor tissues showed that OSC decreased the levels of Nrf2, HO-1, PCNA, cyclin D1, Bcl-2, vimentin, MMP-9, HIF-1α, and VEGF, but increased the expression levels of Bax and E-cadherin, as evidenced by the results of western blotting and IHC assays (Fig. 7D-E ). These results demonstrate that OSC inhibits tumorigenesis of OSCC in vivo. (A and B) . The supernatants were harvested for VEGF measurement by ELISA. (I) SCC-9 and SCC-15 cells were treated as in (C). Western blotting was performed to determine the expression of HO-1, HIF-1α, and VEGF. GAPDH was used as an endogenous control. Data are presented as the mean ± SD of three independent experiments. *P<0.05, **P<0.01 versus Ctrl group, # P<0.05, ## P<0.01 versus siNC group. NS versus OSC group. Ctrl: control; NS: not significant. 
Discussion
In this study, we found that OSC slowed tumorigenesis of OSCC in vitro and in vivo. Key findings were as follows. First, Nrf2 was highly expressed in OSCC tissues and cell lines, and Nrf2 elevation was positively associated with metastases and advanced histological grade and TNM stage, but negatively correlated with differentiation and prognosis of OSCC patients. Second, OSC inhibited activation of the Nrf2/HO-1 signaling pathway in OSCC cells. Third, OSC inhibited proliferation and induced apoptosis of OSCC cells by suppressing HO-1 expression and activation. Fourth, OSC inhibited migration and invasion of OSCC cells by inactivating HO-1 signaling. Fifth, OSC reduced the pro-angiogenic effects of OSCC cells in an HO-1-dependent manner. Finally, OSC reduced tumorigenesis of OSCC in vivo. Overall, these results indicate that OSC reduced the proliferation, apoptosis resistance, migration, invasion, and pro-angiogenesis of OSCC cells partly by blocking the Nrf2/HO-1 axis.
As a redox-sensitive transcription factor, Nrf2 controls the expression of various antioxidant and cytoprotective genes and plays a central role in cellular defense [8] . Owing to its cytoprotective functions, Nrf2 has traditionally been considered a tumor suppressor [33, 34] . However, mounting evidence has demonstrated a negative correlation between Nrf2 expression and tumor progression and outcome [16] [17] [18] 35] . Nrf2 is highly expressed in gastric cancer [16] , non-small-cell lung carcinoma [17] , and gallbladder cancer [35] , and upregulation of Nrf2 in these cancer types is closely associated with several clinical characteristics including differentiation, stage, lymph node metastasis, and poor prognosis. Nrf2 expression has been reported to increase in head and neck squamous cell carcinoma [21] and OSCC [22] . The findings in the present study are in accordance with these previous results; the high expression of Nrf2 in OSCC was positively associated with advanced histological grade, TNM stage, and lymph node and distant metastases, and was inversely associated with differentiation and prognosis of OSCC patients. HO-1, one of the most important effectors of Nrf2, plays crucial roles in the malignant transformation of cancer cells [15, 36] . Aberrant elevations of HO-1 and Nrf2 have been found in many different types of human malignancies, suggesting their oncogenic roles. For instance, a positive correlation was found between the levels of Nrf2 and HO-1 in various cancers [35, 36] . Upregulation of HO-1 increased the aggressiveness of cancer cells, leading to a worse clinical outcome [37] . Indeed, high expression of HO-1 was correlated with advanced stages and poor prognosis of several types of cancers [38] [39] [40] . Moreover, HO-1 was highly expressed in OSCC tissues and was associated with lymph node metastasis [41] . Thus, targeting Nrf2/HO-1 axis may be a promising strategy in the treatment of OSCC. In our study, the levels of Nrf2 and HO-1 were much higher in OSCC cells than in hNOKs, and OSC treatment significantly decreased Nrf2 and HO-1 expression in a dose-dependent manner, indicating that OSC could suppress Nrf2/HO-1 signaling in OSCC cells.
Sustained cell proliferation, uncontrolled cell cycle progression, and escape from apoptosis are the significant hallmarks of human cancers [42] . Emerging evidence has shown that high expression of HO-1 promotes cancer cell proliferation [43] [44] [45] . Overexpression of HO-1 increased the viability and proliferation of murine melanoma cells in vitro and decreased the survival of tumor-bearing mice [46] . HO-1 depletion reduced cell proliferation and induced mitotic delay at G2/M phase in renal carcinoma cells [43] . Incubating chronic myeloid leukemia [44] and ovarian cancer cells [45] with HO-1 inhibitor ZnPP led to the inhibition of cancer cell viability and proliferation. It has been reported that HO-1 has a role in apoptosis resistance in papillary thyroid carcinoma [47] , bladder cancer [48] , and hepatoma [49] . Knockdown of HO-1 expression using siRNA technology or inhibition of HO-1 activity by ZnPP enhanced apoptosis of many cancer cell types induced by different chemotherapeutic agents [15] . Typical biomarkers of cell proliferation, such as PCNA and cyclin D1, were shown to be ubiquitously highly expressed in OSCC [50, 51] . The apoptosis-associated molecules Bax, Bcl-2, and caspase-3 have been reported to be altered in OSCC [52] . Zhao et al [45] . demonstrated that HO-1 increased Bcl-2 expression and decreased Bax expression, which could be reversed by the inhibition of HO-1 expression in ovarian cancer cells. In the present study, we found that OSC abolished the viability, proliferation, and apoptosis resistance of OSCC cells in vitro and slowed tumor growth of OSCC in vivo. OSC decreased the expressions of HO-1 PCNA, cyclin D1, and Bcl-2 and increased the levels of Bax in OSCC cells, paralleling the effects of siHO-1 or ZnPP, suggesting that OSC reduced proliferation and induced apoptosis in OSCC cells by suppressing HO-1 signaling.
Local spreading and distant metastasis are the main causes of poor outcome of patients with OSCC [53] . Increased levels of HO-1 in patients with ovarian cancer [45] and non-small-cell lung carcinoma [40] were positively associated with a high metastatic state and poor prognosis. High expression of HO-1 in OSCC specimens was also associated with lymph node metastasis [41] . HO-1 inducer led to enhanced migratory and invasive abilities of ovarian cancer cells, whereas ZnPP incubation significantly inhibited the migration and invasion of ovarian cancer cells [45] . The migratory and invasive abilities of non-small-cell lung carcinoma cells decreased after siHO-1 transfection, but increase after HO-1 overexpression [40] . In vivo studies demonstrated that ectopic expression of HO-1 in melanoma cells potentiated cancer aggressiveness and increased lung colonization [46] . Similarly, HO-1-overexpressed pancreatic cancer cells formed more nodules in the lungs after intravenous injection than their wild-type counterparts, whereas reduction of HO-1 activity completely abolished metastasis [54] . Epithelial-mesenchymal transition, loss of epithelial markers such as E-cadherin, and gain of mesenchymal markers such as vimentin Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry are essential for tumor spreading and dissemination [55] . In ovarian cancer cells, ZnPP treatment caused obvious downregulation of vimentin [45] . It has been reported that HO-1 increased the expression of metastasis-associated protein MMP-9 in non-small-cell lung carcinoma cells [40] . Here, we demonstrated that OSC treatment markedly reduced OSCC cell migration and invasion in vitro. OSC downregulated the levels of HO-1, vimentin, and MMP-9 and upregulated E-cadherin expression in OSCC cells, which was consistent with the results of siHO-1 or ZnPP treatment. These data indicated that OSC targets HO-1 signaling to hinder the migration and invasion of OSCC cells. Angiogenesis is essential not only for tumor growth but also for metastasis [42] . The pro-angiogenic roles of HO-1 are directly evidenced in human pancreatic cancer [54] , murine melanoma [46] , and murine lung cancer [56] . HO-1 stimulated angiogenesis to accelerate pancreatic carcinoma growth in a mouse model [54] . Tumors derived from mice injected with HO-1-overexpressed melanoma cells displayed excessive vascularization and increased VEGF production [46] . Moreover, ZnPP administration decreased microvessel density and VEGF generation in LL/2 lung cancer in mice [56] . It has been reported that increased HO-1 is positively correlated with elevated expression of HIF-1α and high microvessel density in clinical specimens of bladder cancer [57] . Inhibition of HO-1 by ZnPP decreased the growth and microvessel density of T24 tumors, which may be partly attributed to the suppression of pro-angiogenic factors, particularly VEGF and HIF-1α [57] . In the present study, OSC treatment clearly inhibited the pro-angiogenic effects of OSCC cells and the release of VEGF from OSCC cells in vitro. OSC reduced the levels of HO-1, VEGF, and HIF-1α in OSCC cells, similar to the effects of siHO-1 or ZnPP. These results suggest that OSC suppressed HO-1-mediated pro-angiogenesis of OSCC cells.
Several limitations of this study should be considered. First, we demonstrated that OSC reduced Nrf2/HO-1-dependent proliferation, mobility, and pro-angiogenesis of OSCC cells in vitro only by conducting inhibitory experiments using siRNA or ZnPP treatment. It would be interesting to further explore the rescue effects of HO-1 overexpression on OSC-treated OSCC cells. Second, we found that OSC hindered the proliferation, migration, invasion, and pro-angiogenesis of OSCC cells in vitro by inactivating HO-1 signaling; however, we only probed that OSC retards tumorigenesis of OSCC in vivo, involving the expression changes of HO-1 and its downstream molecules. Thus, further investigation is required to elucidate whether OSC suppression of OSCC carcinogenesis is directly dependent on HO-1 signaling. In future studies, we aim to construct an OSCC cell line with stable HO-1 depletion to establish a xenograft mouse model. Then, we will explore whether the inhibitory effects of OSC on OSCC directly rely on HO-1 signaling, similar to the in vitro findings.
Conclusion
In summary, our study provides evidence that OSC represses Nrf2/HO-1-dependent growth, metastasis, and pro-angiogenesis of OSCC. We found that Nrf2 was highly expressed in OSCC tissues and cell lines. Nrf2 elevation was positively correlated with growth, metastasis, and poor outcome of OSCC. Functional experiments revealed that OSC decreased proliferation, migration, invasion, and pro-angiogenesis, and increased the apoptosis of OSCC cells, in part by targeting the Nrf2/HO-1 axis. Therefore, OSC may be a potential therapeutic agent for OSCC.
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